BioMarin Pharmaceutical Inc.
BMRN
$60.43
$1.903.25%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 17.03% | 4.08% | 15.92% | 14.84% | 15.65% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 17.03% | 4.08% | 15.92% | 14.84% | 15.65% |
| Cost of Revenue | -30.96% | 47.19% | -0.91% | -6.02% | -227.12% |
| Gross Profit | 22.17% | -39.16% | 29.22% | 36.46% | 292.30% |
| SG&A Expenses | 21.59% | 5.89% | -11.69% | -8.76% | 2.73% |
| Depreciation & Amortization | -49.79% | -3.23% | -66.11% | -66.10% | -36.66% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 15.70% | 30.23% | -7.28% | -8.61% | -5.34% |
| Operating Income | 21.83% | -141.00% | 129.87% | 185.35% | 491.69% |
| Income Before Tax | -116.01% | -119.58% | 125.43% | 125.58% | 777.73% |
| Income Tax Expenses | -56.55% | -84.42% | 129.69% | 210.35% | 4,364.89% |
| Earnings from Continuing Operations | -137.28% | -128.98% | 124.43% | 109.43% | 513.22% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -137.28% | -128.98% | 124.43% | 109.43% | 513.22% |
| EBIT | 21.83% | -141.00% | 129.87% | 185.35% | 491.69% |
| EBITDA | 13.33% | -121.22% | 101.10% | 132.45% | 241.73% |
| EPS Basic | -136.98% | -128.74% | 122.35% | 107.14% | 506.11% |
| Normalized Basic EPS | 25.20% | -119.42% | 123.32% | 146.43% | 767.39% |
| EPS Diluted | -137.57% | -129.25% | 124.28% | 108.02% | 644.69% |
| Normalized Diluted EPS | 29.07% | -120.11% | 129.33% | 152.72% | 756.03% |
| Average Basic Shares Outstanding | 0.81% | 0.84% | 0.94% | 1.11% | 1.17% |
| Average Diluted Shares Outstanding | -2.22% | -2.59% | -1.70% | -1.40% | 2.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |